

Radwan Massoud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2048058/publications.pdf>

Version: 2024-02-01

41
papers

407
citations

932766

10
h-index

794141

19
g-index

41
all docs

41
docs citations

41
times ranked

812
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 2867-2874.	2.0	100
2	Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1074-1077.	1.3	38
3	Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. <i>Nature Communications</i> , 2019, 10, 2891.	5.8	36
4	Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 506-508.	0.2	36
5	Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2017, 52, 918-921.	1.3	32
6	Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 617-623.	0.2	23
7	Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 179-185.	0.2	19
8	Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e441-e444.	0.2	19
9	Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 620-624.	1.3	14
10	Enhanced Immune Reconstitution of T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 841-850.	0.6	13
11	A Pin1/PML/P53 axis activated by retinoic acid in NPM-1c acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 3090-3099.	1.7	11
12	Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Virology</i> , 2017, 95, 36-41.	1.6	10
13	Site specific diagnostic yield of endoscopic biopsies in Gastrointestinal Graft-versus-Host Disease: A tertiary care Center experience. <i>Current Research in Translational Medicine</i> , 2019, 67, 16-19.	1.2	9
14	Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection. <i>Bone Marrow Transplantation</i> , 2021, 56, 1478-1481.	1.3	9
15	Trends in hematopoietic stem cell transplant activity in Lebanon. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 315-320.	0.6	8
16	Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1732-1735.	0.6	5
17	Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2017, 52, 1187-1190.	1.3	4
18	Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 2745-2747.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 368-374.	0.2	3
20	Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients. <i>Leukemia Research</i> , 2021, 105, 106568.	0.4	3
21	Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1548-1555.	1.3	3
22	Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 371-376.e1.	0.2	2
23	Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4624-4624.	0.6	2
24	Progressive multifocal leukoencephalopathy in patients receiving rituximab and cyclophosphamide after haplo-identical T-cell replete transplantation and review of the literature. <i>Current Research in Translational Medicine</i> , 2017, 65, 127-132.	1.2	1
25	Haploidentical related donor allogeneic hematopoietic stem cell transplantation for patient aged older than 76 years with refractory acute myeloid leukemia. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 175-177.	0.6	1
26	The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study. <i>Current Research in Translational Medicine</i> , 2020, 68, 51-58.	1.2	1
27	Post Transplant Brentuximab Maintenance Appears More Effective Than Post Transplant Salvage Brentuximab for Relapsed/Refractory Hodgkin s Lymphoma. <i>Blood</i> , 2016, 128, 5357-5357.	0.6	1
28	Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML. <i>Blood</i> , 2016, 128, 5872-5872.	0.6	1
29	Post Transplant Brentuximab Maintenance Appears more Effective than Post Transplant Salvage Brentuximab for Relapsed /Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S68.	0.2	0
30	Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: a Single-Center Study at the American University of Beirut Medical Center (AUBMC). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S122-S123.	0.2	0
31	Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S34-S35.	0.2	0
32	Real Life Experience with Plerixafor and Granulocyte Colony-Stimulating Factor for Mobilization of Autologous Peripheral Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S311.	0.2	0
33	Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patient Aged over 76 Years with Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S196-S197.	0.2	0
34	Mutations in Human Histone H3 are Pre-Leukemic Events and Promote Hematopoietic Stem Cell Expansion and Leukemic Aggressiveness. <i>Experimental Hematology</i> , 2018, 64, S55-S56.	0.2	0
35	S117 THE ROLE OF ANTI-T LYMPHOCYTE GLOBULIN WITH THIOTEPA AND BUSULFAN AND FLUDARABINE BASED CONDITIONING IN PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANT AND POST TRANSPLANT CYCLOPHOSPHAMIDE. <i>HemaSphere</i> , 2019, 3, 10-11.	1.2	0
36	Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC). <i>Blood</i> , 2016, 128, 5824-5824.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Bendamustine Demonstrates Promising Activity in Post-Brentuximab Failure Hodgkin Lymphoma Patients Who Had Also Failed a Prior Autologous HCT and Facilitates Successful Bridging to Allogeneic HCT. <i>Blood</i> , 2016, 128, 5359-5359.	0.6	0
38	Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5238-5238.	0.6	0
39	Role of 2677G>T>A Genetic Polymorphism in the ABCB1 Drug Transporter in the Interaction between Voriconazole and Cyclosporine and Cyclosporine Related Nephrotoxicity After Allogeneic Stem Cell Transplantation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018. WCP2018. PO4-6-6.	0.0	0
40	Imatinib Mesylate Is Safe and Effective in Maintaining Cytogenetic and Molecular Response Achieved with 1 Year Nilotinib First Line in Newly Diagnosed Chronic Myeloid Leukemia: Preliminary Results of a Prospective Clinical Trial. <i>Blood</i> , 2018, 132, 5445-5445.	0.6	0
41	Assessment of Caries Index and Fluoride Intake in a Pediatric Middle Eastern Population. <i>Journal of Contemporary Dental Practice</i> , 2020, 21, 1098-1104.	0.2	0